Jacques Dumas
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
Papers in
-
- Melanoma and MAPK Pathways 10
- Biochemical and Molecular Research 5
- Enzyme Catalysis and Immobilization 4
- Angiogenesis and VEGF in Cancer 4
-
- Synthesis and biological activity 4
- Co-authors
- Scott M. Wilhelm (5 shared papers)Mark John Lynch (3 shared papers)Roger A. Smith (6 shared papers)Timothy B. Lowinger (5 shared papers)Christopher J. Carter (1 shared paper)Ronit Simantov (1 shared paper)Brian E. Schwartz (1 shared paper)Susan L. Kelley (1 shared paper)
- Journals
- Bioorganic & Medicinal Chemistry Letters (11 papers)Tetrahedron Letters (4 papers)Journal of the American Chemical Society (3 papers)Expert Opinion on Therapeutic Patents (2 papers)ACS Chemical Biology (1 paper)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Jacques Dumas
51 papers receiving 4.2k citations
Jacques Dumas's Hit Papers
Peers
Comparison fields: 5 of 117
- Hepatology 491
- Oncology 1.1k
- Organic Chemistry 1.2k
- Pathology and Forensic Medicine 564
- Cancer Research 409
Countries citing papers authored by Jacques Dumas
This map shows the geographic impact of Jacques Dumas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Dumas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Dumas more than expected).
Fields of papers citing papers by Jacques Dumas
This network shows the impact of papers produced by Jacques Dumas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Dumas. The network helps show where Jacques Dumas may publish in the future.
Co-authors
The 25 scholars most cited alongside Jacques Dumas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Hit paper breakdown → | 2006 | 1551 |
| 2 | Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Hit paper breakdown → | 2010 | 1133 |
| 3 | 1992 | 193 | |
| 4 | 2007 | 145 | |
| 5 | 2002 | 131 | |
| 6 | 2004 | 107 | |
| 7 | 2002 | 96 | |
| 8 | 1999 | 83 | |
| 9 | 1992 | 69 | |
| 10 | 2001 | 68 | |
| 11 | 1992 | 65 | |
| 12 | 2000 | 46 | |
| 13 | 2012 | 43 | |
| 14 | 2006 | 40 | |
| 15 | 2001 | 40 | |
| 16 | 2012 | 39 | |
| 17 | 2000 | 39 | |
| 18 | 2003 | 38 | |
| 19 | Recent developments in the discovery of protein kinase inhibitors from the urea class. | 2004 | 32 |
| 20 | 2003 | 32 |
About Jacques Dumas
Jacques Dumas is a scholar working on Molecular Biology, Organic Chemistry, Biochemistry, Cancer Research and Pharmaceutical Science, having authored 53 papers that have together received 4.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (10 papers), Biochemical and Molecular Research (5 papers), Eicosanoids and Hypertension Pharmacology (5 papers), Cancer Mechanisms and Therapy (4 papers), Enzyme Catalysis and Immobilization (4 papers), Protease and Inhibitor Mechanisms (4 papers), Synthesis and biological activity (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). The work is most often cited by research in Hepatology (491 citations), Oncology (1.1k citations), Organic Chemistry (1.2k citations), Pathology and Forensic Medicine (564 citations) and Cancer Research (409 citations). Jacques Dumas has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Scott M. Wilhelm, Mark John Lynch, Roger A. Smith, Timothy B. Lowinger, Christopher J. Carter, Ronit Simantov, Brian E. Schwartz, Susan L. Kelley, Lila Adnane and Gunnar Schütz. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Tetrahedron Letters, Journal of the American Chemical Society, Expert Opinion on Therapeutic Patents and ACS Chemical Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.